Doxepin is a tricyclic antidepressant that is widely prescribed for the treatment of mild depression. In this study, hair samples collected from a patient receiving 25 mg of doxepin daily were analyzed. Doxepin was administered to the patient for 4 months (June 15 to October 15, 1996). Five hair samples were collected: 1 and 3 months after doxepin therapy began and 1, 3, and 5 months after drug therapy ended. Solid-phase extraction was employed to isolate doxepin and its major metabolite desmethyldoxepin from the hair matrix, and gas chromatography-mass spectrometry (GC-MS) was used for quantitation of both drugs. Six-point standard curves (0.25-20 ng/mg) were prepared for both compounds with an internal standard (doxepin-d3). The standard curves for doxepin and desmethyldoxepin were linear over the range reported and had correlation coefficients of 0.984 and 0.985, respectively. The limit of quantitation for both analytes was 0.25 ng/mg of hair. In addition, the replicate analysis of control hair preparations was performed at two levels (2 ng/mg and 15 ng/mg) to determine intra-and interday variability. Doxepin and desmethyldoxepin were not detected in the patient's sample collected I month after doxepin therapy began.
Introduction
Doxepin is a tricyclic antidepressant (TCA) first introduced in 1969. It is recommended for the treatment of depression, espe-cially depression accompanied by anxiety. Physicians often prescribe doxepin because of its sedative properties and because its anticholinergic effects are minimized. It is believed that the inhibition of the reuptake of norepinephrine and serotonin and the subsequent stimulation by these neurotransmitters provides the primary antidepressant action (1) . In fact, doxepin is a weak inhibitor of the reuptake of neurotransmitters and is thought to exhibit antidepressant activity similar to the other TCAs. Other therapeutic uses for doxepin include the treatment of chronic pain, peptic ulcer disease, and some dermatologic disorders (1) (2) (3) .
Doxepin is, chemically, a mixture of cis and trans isomers of 3-(dibenz[b~]oxepin-11(6H)-ylidene)-N,N-dimethylpmpylamine. Doxepin shows a 10-to 15-fold variability among individuals in metabolism and elimination rates (4) . This leads to great individual differences in plasma concentrations. Peak plasma concentrations of doxepin range from 8.8 to 45.8 ng/mL and occur between 2 and 4 h after oral administration of 75 nag of the drug (5) . The half-life of doxepin ranges from 8 to 24 h (mean, 16.8 h), and the half-life of desmethyldoxepin is 33 to 80 h (mean, 51.3 h) (5) .
Doxepin is well absorbed in the small intestine but undergoes considerabJe (55--87%) first-pass demethyJation (5, 6) . It is highIy lipid-soluble and therefore readily crosses the blood-brain barrier (7) . The volume of distribution of doxepin is 9 to 33 L/kg (mean, 20 Ukg) (5, 8, 9) . The primary route of elimination of doxepin and its metabolites is urinary excretion, although they may also be excreted in feces via bile (1) .
TCAs can produce side effects even when used within therapeutic range. Some common side effects include cardiac arrhythmia, seizures, dry mouth, blurred vision, constipation, urinary retention, sexual dysfunction, and weight gain (1, 10, 11) . Toxicity occurs when the plasma level is only three times the upper limit of the therapeutic range (4). This, coupled with the fact that the depressed are often prone to suicide, makes doxepin a potentially dangerous drug.
It has been determined that more than 15% of patients with major depression engage in self-poisoning (12) . A study by Callaham and Kassel (13) found that TCAs were the fourth most common overdose seen in emergency rooms in 1982. In a 1995 study by Litovitz et al. (14) , doxepin accounted for 5.1% of all antidepressant ingestions. This is a significant decrease from 1987, when doxepin accounted for 12.6% of all antidepressant ingestions (15) .
Forensic applications of drug testing in hair include the determination of chronic poisoning and illegal drug use. There are some rare instances in which typical toxicology specimens are not available, such as badly decomposed bodies or poisonings where the victim did not die immediately or suspicions were raised months later. In these cases, hair may be available as a substitute means of obtaining the desired information.
The aim of this study was to investigate how the concentrations of doxepin and its pharmacologically active metabolite, desmethyldoxepin, can be measured during and following drug therapy with a low dose (25 mg daily) of doxepin. A gas chromatography-mass spectrometry (GC-MS) method for analyzing the drug and metabolite concentrations in hair was developed and validated. Accuracy and precision were considered by analyzing intra-and interday variabilities of low and high controls.
Experimental

Instrumentation
The GC-MS system consisted of a Hewlett Packard (Palo Alto, CA) 6890 series injector, an HP 6890 series GC system and an HP 5973 mass selective detector. An HP-5MS capillary column (30 m • 250-pro i.d., 0.25-1Jm film thickness) was used for separation. The hair pulverizer used was from Crescent (Lyons, IL), and the heating block was from Fisher Scientific (Itasca, IL). The VacElut TM extraction manifold was from Analytichem International (Varian, Harbor City, CA), and the centrifuge was from Damon/ IEC Division (Needham Heights, MA). The Meyer N-EVAP ~ analytical evaporator (Organomation Assoc., Inc., Northborough, MA) was also used.
Chemicals, reagents, and specimens
Doxepin, desmethyldoxepin (both 1 mg/mL in methanol), and the deuterated internal standard doxepin-d3 (100 lJg/mL in methanol) were purchased from Radian International (Austin, TX). Methanol (high-performance liquid chromatographic 
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Standards and controls
The doxepin and desmethyldoxepin standard stock solutions (1 mglmL) were diluted with methanol to concentrations of 10, 2, and 1 pg/mL. The doxepin-d3 standard stock solution (100 IJg/mL) was diluted with methanol to 10 pg/mL. Six-point standard curves were prepared for doxepin and desmethyldoxepin by using 50-mg aliquots of the negative hair spiked with methanolic solutions of both drugs to achieve the following concentrations of standard hair preparations: 0.25, 0.50, 1.0, 5.0, 10.0, and 20.0 ng/mg.
In addition, two levels of controls were prepared. The low controis (2 ng/mg) were made by adding 50 IJL of both 2-1Jg/mL doxepin and desmethyldoxepin solutions to 50 mg of pulverized negative hair samples. The high controls (15 ng/mg) were prepared by adding 75 IJL of the lO-pg/mL solutions of both doxepin and desmethyldoxepin to 50 mg of pulverized negative hair.
Analytical procedure
The patient's hair samples were washed in deionized water and allowed to dry at room temperature. They were then pulverized, and 50-mg aliquots were analyzed in triplicate. Twenty microliters of the 10-lJg/mL solution of the internal standard (doxepind3) was added to the hair samples, standards, and control preparations. This was followed by the addition of 0.1M HCl (3 mL). The test tubes were capped, vortex mixed, and incubated overnight (18 to 24 h) at 50~ The tubes were removed from the heating block and allowed to cool down before being centrifuged for 5 rain (400 x g). The supernatant was transferred to clean tubes, 1 mL 1.93M acetic acid was added to each test tube, and they were vortex mixed. Ten milliliters of deionized water was then added to each tube.
The HCX columns were conditioned as follows: methanol (3 mL), deionized water (3 mL), and 1.93M acetic acid (1 mL). The samples were added to the columns and slowly drawn through before drying 1-2 min. The columns were washed with 3 mL of deionized water (dried 1-2 rain), 1 mL of 0.1M HCI (dried 1-2 min) and 3 mL of methanol (dried 5 min). The doxepin, desmethyldoxepin, and doxepin-d3 were eluted by allowing 3 mL of the methylene chloride/isopropanol/ammonium hydroxide (78:20:2, vh~/v) mixture to pass through the columns.
All samples were then evaporated to dryness under a stream of air. The drug residue was reconstituted in acetonitrile (40 pL). The samples were transferred to autosampler vial inserts, and the vials were crimped. The samples were derivatized by adding BSTFA with 1% TMCS (40 pL) with a syringe and vortex mixed. After incubating for 15 rain at 60~ the samples were cooled and analyzed using GC-MS.
Chromatographic method
The injector was working in the splitless mode, and a 1-pL volume was injected. The injector temperature was 270~ The flow rate of the cartier gas (helium) was 1.2 mL/min. The initial GC oven temperature of 130~ was held for 1 min, then it was increased at the rate of 12~ until it reached 280~ This temperature was maintained for 3 min. The MS ion source 
Precision and accuracy
Quantitation of doxepin and desmethyldoxepin was performed using an internal standard method. Six-point standard curves were prepared by linear least-square regression analysis of the ratio of the peak area of doxepin and desmethyldoxepin to the peak area of the internal standard (doxepin-d3) as a function of concentration. Peak-area ratios were determined for the controls. Control concentrations were then calculated using the standard curve. Intraday variability was determined by analyzing three replicates of low controls (2.00 ng/mg) and three high controls (15.00 ng/mg) for both doxepin and desmethyldoxepin prepared in negative hair. Interday variability was determined over a period of 5 weeks. The mean measured concentrations and standard deviations were calculated based on the intra-and interday variability populations. The percent relative accuracy was determined using the following equation: [(Mean Measured Concentration -Theoretical Concentration)/Theoretical Concentration] • 100%. Figure 1 presents the total ion chmmatogram of doxepin, doxepin-d3, and desmethyldoxepin. The retention time for doxepin and doxepin-d3, was 11.48 rain, and the retention time for desmethyldoxepin-TMS was 12.65 rain. All chromatograrns were recorded over the time range of 10.00 to 16.50 min. Standard curves for doxepin and desmethyldoxepin were linear over the range of drugs assayed (0.25 to 20 ng/mg hair). The correlation coefficients of the standard curves were 0.984 for doxepin and 0.985 for desmethyldoxepin. The limit of quantitation was arbitrarily established to be 0.25 ng/rng, and it was the lowest concentration of the standard curve. The limit of detection was the lowest concentration at which the signalto-noise ratio was 5:1. Figures 2 and 3 show the selected ion chromatograms for the negative hair preparation and the patient's hair sample, respectively. The mean concentration of doxepin in the patient!s hair was 0.59 ng/mg. Tables I and II present the accuracy and precision of the doxepin and desmethyldoxepin control hair preparations, respectively. The intraday variability was determined by analyzing three replicates of controls (2 and 15 ng/mg hair) prepared in negative hair on a single day. The interday variability was determined over a period of 5 weeks on 8 separate days. doxepin in the patient's hair samples. Administration of doxepin began on 6-15-96 and ended on 10-15-96. As Table III shows, it was not until 3 months after drug therapy began that a detectable amount of drug and metabolite was present in the hair. These data suggest that detectable quantitites of doxepin may be measured in hair sometime between I and 3 months after initiating therapy. Doxepin may appear even earlier if hair is collected closer to the skin and higher doses are administered. Doxepin and desmethyldoxepin concentrations were highest in the hair sample collected 1 month after the conclusion of drug therapy. Because specimens were collected at approximately 2-month intervals, it is possible that peak drug concentrations were reached sometime before or after this sample was collected. Five months after the conclusion of therapy, doxepin and desmethyldoxepin concentrations fell below the limit of quantitation. The concentration of doxepin and its metabolite in hair during and following drug therapy is shown in Figure 4 . 
Results
Discussion
Only two previous studies have analyzed doxepin in hair. In the Couper et al. (16) study, 21 postmortem cases were analyzed for antidepressant and antipsychotic drugs using liquid-liquid extraction and GC-MS analysis. Antidepressants A were found in 17 of these cases; only two of these cases were positive for doxepin. The doxepin concentrations were 7.7 and 87 ng/mg hair. No information was provided as to the amount of doxepin ingested. Pragst et al. (17) analyzed hair for TCAS and their nor-metabolites using solid-phase extraction and GC-MS. In six cases, hair samples were analyzed for doxepin and desmethyldoxepin. The concentrations ranged from 0.99 to 3.0 B ng/mg hair for doxepin and 0.52 to 2.1 ng/mg hair for desmethyldoxepin. The daily dose was known in only three of these cases; the range was 0.13 to 0.46 mg/kg. In our study, concentrations for doxepin and desmethyldoxepin were always less than 1.0 ng/mg hair. One month after the patient began taking doxepin, the drug and its metabolite were not detected. Three months after the patient began drug therapy, doxepin and desmethyldoxepin were detected at levels that fell below the quantita-C tion limit. The highest concentrations of doxepin and desmethyldoxepin were observed 1 month after the patient had stopped taking doxepin (mean, 0.59 ng/mg for doxepin and 0.40 ng/mg for desmethyldoxepin). Seven weeks later, the doxepin and desmethyldoxepin levels were 0.45 ng/mg and 9 ~,:= 0.25 ng/mg, respectively. Five months after drug therapy had ended, the levels were once again below the quantitation limit (mean, 0.09 ng/mg for doxepin and 0.04 ng/mg for desmethyldoxepin). The concentrations of both the drug and its metabolite were consistently lower than other reported values because the patient was taking 25 mg of doxepin daily for only 4 months.
Pragst et al. (17) showed that the concentration of the normetabolite in hair was always lower than the concentration of the parent drug. In his study, 43 hair samples were analyzed for four different TCAs and their nor-metabolites. Only 4 of these 43 cases had metabolite concentrations greater than the parent drug. In our study, doxepin and desmethyldoxepin were detected in all samples except those collected 1 month after therapy began (7-24-96 ). The concentration of doxepin was always higher than Dates of hair collection the concentration of desmethyldoxepin. One possible reason the parent drug is seen in higher concentrations in the hair than the nor-metabolite is that the nor-metabolite is less lipophilic than the parent drug. The same observation, that is, accumulation of more non-polar parent drugs, has been reported for other compounds such as cocaine and heroin. According to Pragst et al. (17) , TCAs can be detected in normally kept hair for approximately 1 year after drug therapy is discontinued without a drastic concentration decrease. The patients in that study were being permanently treated with the TCA and had been taking the drug for at least 1 year prior to sampling. In this study, the concentrations were below the quantitation limit 5 months after doxepin administration was stopped (0.09 ng/rng for doxepin and 0.04 ng/mg for desmethyldoxepin). It should be kept in mind, however, that in our study, the patient was taking a very low dose of doxepin (25 mg/day) for only a short period prior to sample collection. Our data show that under these conditions, hair levels of doxepin and its major metabolite, desmethyldoxepin, were detectable only up to 5 months after drug therapy ended.
Conclusion
The analytical method presented for the determination of doxepin and its major metabolite desmethyldoxepin employing solidphase extraction and GC-MS is accurate and precise enough for quantitation of both drugs in hair samples. A 25-mg daily dose of doxepin produced concentrations of the drug and its metabolite desmethyldoxepin in hair samples below I ng/mg each. Less of the demethylated metabolite than of the parent drug accumulated in hair. In addition, the highest concentration of doxepin and its major metabolite was observed 1 month after drug therapy was discontinued. Five months after doxepin therapy was terminated, the drug and its metabolite were still present in the patient's hair.
